Filing Details
- Accession Number:
- 0001209191-14-042626
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-06-19 17:20:50
- Reporting Period:
- 2014-06-17
- Filing Date:
- 2014-06-19
- Accepted Time:
- 2014-06-19 17:20:50
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1373707 | Tetraphase Pharmaceuticals Inc | TTPH | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1296998 | Guy Macdonald | 480 Arsenal St. Suite 110 Watertown MA 02472 | President And Chief Executive | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2014-06-17 | 15,000 | $0.87 | 15,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2014-06-17 | 15,000 | $12.28 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) | Disposition | 2014-06-17 | 15,000 | $0.00 | 15,000 | $0.87 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
35,849 | 2019-09-10 | No | 4 | M | Direct |
Footnotes
- The exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2013.
- The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $11.99 to $12.52 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- Fully vested.